Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperidine SCHEMBL27915255 | 0.98 | ALDH1A1 (0.58) | ALDH1A1LMNAHSD17B10TSHROPRM1 | |
| Ethyl Acetate SCHEMBL28224693 | 0.98 | ALDH1A1 (0.64) | ALDH1A1LMNAHSD17B10TSHROPRM1 | |
| Ethyl Acetate SCHEMBL28024376 | 0.91 | ALDH1A1 (0.61) | ALDH1A1LMNAHSD17B10TSHROPRM1 | |
| Piperazine SCHEMBL6093828 | 0.89 | ALDH1A1 (0.70) | ALDH1A1LMNAHSD17B10TSHROPRM1 | |
| Piperazine SCHEMBL27792846 | 0.86 | ALDH1A1 (0.67) | ALDH1A1LMNAHSD17B10TSHROPRM1 | |
| Cyclohexane SCHEMBL509143 | 0.86 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Cyclohexane SCHEMBL416739 | 0.86 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Cyclohexane SCHEMBL509553 | 0.86 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Cyclohexane SCHEMBL5908851 | 0.86 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Cyclohexane SCHEMBL1172967 | 0.86 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117845051-A | Temperature-control type hydrophobic extractant for homogeneously separating gold (III), preparation method thereof and extraction method thereof | 山东大学 | 2024-04-09 | — | — | CN | claimed |
| CN-101809015-A | Salts of CGRP antagonists, method for the production thereof and use thereof as medicaments | BOEHRINGER INGELHEIM INT | 2010-08-18 | — | — | CN | claimed |
| CN-117845051-B | Temperature-control type hydrophobic extractant for homogeneously separating gold (III), preparation method thereof and extraction method thereof | 山东大学 | 2026-04-10 | — | — | CN | disclosed |
| CN-117845051-A | Temperature-control type hydrophobic extractant for homogeneously separating gold (III), preparation method thereof and extraction method thereof | 山东大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-117845051-A | Temperature-control type hydrophobic extractant for homogeneously separating gold (III), preparation method thereof and extraction method thereof | 山东大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-101809015-A | Salts of CGRP antagonists, method for the production thereof and use thereof as medicaments | BOEHRINGER INGELHEIM INT | 2010-08-18 | — | — | CN | disclosed |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090036469-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | disclosed |
| EP-1699753-A4 | IMPROVED PROCESS FOR THE PREPARATION OF ENTACAPONE | SUVEN LIFE SCIENCES LTD (IN) | 2008-12-31 | — | — | EP | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008039882-A1 | A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST | SANOFI-AVENTIS U.S. LLC (US) | 2008-04-03 | — | — | WO | disclosed |
| EP-1699753-A1 | IMPROVED PROCESS FOR THE PREPARATION OF ENTACAPONE | Suven Life Sciences Limited (IN) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005063693-A1 | IMPROVED PROCESS FOR THE PREPARATION OF ENTACAPONE | SUVEN LIFE SCIENCES LTD (IN) | 2005-07-14 | — | — | WO | disclosed |
| US-6361940-B1 | IMMOBILIZATION; GENETIC ENGINEERING | QIAGEN GENOMICS, INC. | 2002-03-26 | — | — | US | disclosed |
| CN-1305470-A | Amidine compounds | JAPAN TOBACCO INC (JP) | 2001-07-25 | — | — | CN | disclosed |
| CN-1021733-C | Process for preparation of indolylpiperidine compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1993-08-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036469-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | PTGDR2, PTGDR, PTGER2 | ALDH1A1 802/4885LMNA 4152/4885HSD17B10 1487/4885 |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | ALDH1A1 1587/4885LMNA 1109/4885HSD17B10 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.